Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Cyproterone acetate is used for topical treatment of diseases dependent on male hormones.

Baricitinib improved hair loss and arthritis in a lupus patient.

Etanercept, a psoriasis treatment, caused hair loss in a patient.

Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.

Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.

Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.

Blocking CCR5 can prevent and improve hair loss in alopecia areata.

Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.

Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Both treatments improved alopecia areata, but methotrexate caused more skin darkening, while triamcinolone caused skin lightening and thinning.

Upadacitinib may cause hair loss.

Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.

Baricitinib is a promising treatment for alopecia areata.

Intramuscular triamcinolone and pulse therapy with oral predonine are effective for alopecia areata with manageable side effects, but better relapse prevention is needed.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

Candida antigen is an effective and promising treatment for alopecia areata.

SCD-153 shows promise as an effective topical treatment for alopecia areata.

Blocking certain proteins on immune cells may help treat alopecia areata.

Methotrexate and azathioprine are equally effective and well-tolerated for treating lichen planopilaris.

A woman with rheumatoid arthritis lost all her hair during adalimumab treatment, and stopping the drug didn't help.

Azathioprine can cause unexpected hair loss and severe bone marrow issues, so careful monitoring is needed.

Blocking certain proteins can significantly regrow hair in severe alopecia areata.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.